GlassScriptPhysician profile
Martin C Johnson
NPI 1922116557
$3,617.73
in general payments reported to CMS, 2019-2025
36 companies · $588 in 2025
The $588 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $420 · 2021: $408 · 2022: $376 · 2023: $677 · 2024: $433 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.44 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,309.77 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $286.91 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $266.63 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| United Therapeutics Corporation | $192.85 | 2020-2025 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $153.43 | 2019-2025 | Airsupra |
| Harmony Biosciences LLC | $122.59 | 2020-2023 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.09 | 2019-2023 | Stiolto Respimat, Spiriva Respimat, Ofev |
| Sanofi-Aventis U.S. LLC | $99.95 | 2023 | |
| Sunovion Pharmaceuticals INC. | $98.06 | 2019 | |
| Mylan Specialty L.P. | $72.82 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $65.37 | 2024 | Voquezna |
| Avadel Cns Pharmaceuticals, LLC | $59.07 | 2023-2024 | Lumryz |
| Philips North America LLC | $58.12 | 2021-2023 | |
| Genentech USA, INC. | $57.77 | 2020-2025 | Xolair |
| Amgen INC. | $53.43 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $47.23 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $46.73 | 2025 | Glassia, Cuvitru |
| Baxter Healthcare | $46.72 | 2023 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Electromed, INC. | $43.52 | 2019-2024 | Smartvest |
| Arbor Pharmaceuticals, INC. | $41.89 | 2019-2022 | |
| Gilead Sciences, INC. | $41.69 | 2021-2022 | |
| Genzyme Corporation | $41.69 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $34.68 | 2021-2023 | Dupixent |
| Viatris Specialty LLC | $32.43 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $32.39 | 2025 | Acthar |
| Eusa Pharma (US) LLC | $23.86 | 2020 | |
| Grifols USA, LLC | $23.64 | 2019 | |
| Allergan, INC. | $23.33 | 2020 | |
| Genentech, INC. | $22.65 | 2019 | |
| Itamar Medical INC | $18.99 | 2024 | Watchpatone |
| Bayer Healthcare Pharmaceuticals INC. | $17.13 | 2024 | |
| Abiomed | $15.85 | 2019 | |
| Pharming Healthcare, INC. | $15.78 | 2023 | Ruconest |
| Strongbridge US INC. | $13.46 | 2019 | |
| Advanced Respiratory, INC | $11.72 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $11.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.